08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral sclerosis...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Microsomal prostaglandin E synthase-1 (PTGES; mPGES-1); prostaglandin E2 (PGE2)

Neurology INDICATION: Pain Cell culture, human blood and guinea pig studies identified PTGES inhibitors that could help treat arthritis-related pain. In in vitro enzymatic activity assays, two compounds based on different scaffolds inhibited PTGES activity with IC50...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus Microsomal prostaglandin E synthease-1 (PTGES; mPGES-1) Mouse studies suggest inhibiting PTGES could help treat...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

GRC 27864: Phase I start

Glenmark said it will "soon" begin a U.K. Phase I trial of oral GRC 27864. Glenmark is developing GRC 27864 under a 2012 deal with Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) to develop...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Cadila Pharmaceuticals, NovaSaid deal

NovaSaid and Cadila partnered to develop NovaSaid's therapeutic candidates for inflammation and pain, including rheumatoid arthritis (RA). The companies will collaborate on preclinical and clinical testing. Development will be conducted at Cadila's facility in Ahmedabad,...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

LY3023703: Phase II started

Eli Lilly disclosed in its 2Q13 earnings that it began a Phase II trial to evaluate LY3023703. The product is also in Phase II testing to treat pain following wisdom teeth removal. Eli Lilly and...
07:00 , Mar 11, 2013 |  BioCentury  |  Emerging Company Profile

FPRT Bio: Neutralizing neuroinflammation

FPRT Bio Inc. is developing a protein therapeutic that could halt neurodegeneration in amyotrophic lateral sclerosis and Parkinson's disease by blocking inflammatory signaling that causes neuronal cell death. FPRT's sole asset is XPro1595, a subcutaneously administered...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Rosetta's Nordic preferences

Karolinska Development AB expects that selling a stake in some of its portfolio to a syndicate led by Rosetta Capital Ltd. will provide enough cash to advance the entire portfolio to a point at which...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Company News

GNT Pharma, Toyota Tsusho Corp. deal

Global Neurotech (GNT) Pharma Co. Ltd., Yongin-si, South Korea   Toyota Tsusho Corp. (Tokyo:8015), Tokyo, Japan   Business: Neurology   Toyota received exclusive rights to promote GNT's products in Japan. GNT's pipeline includes: Neu2000, a NMDA...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Clinical News

AAD-2004: Phase I started

Neurotech began a double-blind, placebo-controlled Phase I trial to evaluate AAD-2004 in 32 healthy volunteers. Neurotech Pharmaceuticals Inc., Lincoln, R.I.   Product: AAD-2004   Business: Neurology   Molecular target: Microsomal prostaglandin E synthase-1 (PTGES) (mPGES-1)   Description:...